ArticleNeurology and therapy2026
Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05096221 (A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDuchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease. The first approved DMD gene therapy, delandistrogene moxeparvovec, was evaluated in the phase 3, two-part, randomized, placebo-controlled EMBARK trial (NCT05096221), which did not meet statistical significance for its primary endpoint assessed at the end of Part 1 (Week 52). To gather patient experience data possibly not captured by traditional clinical outcome assessments, a qualitative in-trial interview substudy was conducted among caregivers (parents) (≥ 18 years) of male patients (≥ 4 to < 8 years with DMD) who completed Part 1 (Week 52) of EMBARK.
methodsSemi-structured interviews, conducted with 23 parents within 14 days after the last EMBARK Part 1 visit, assessed DMD-related symptoms and impacts prior to EMBARK, perceptions of meaningful outcomes based on hypothetical examples using DMD-specific Caregiver Global Impression measures for Severity (CaGI-S) and Change (CaGI-C), and observed changes during the trial. Initial analyses were blinded to treatment assignment; follow-up analyses examining changes in physical activities were unblinded.
resultsDebriefing questions demonstrated parents' understanding and correct interpretation of items and response options. Most parents indicated that "no change" or a 1-point improvement on CaGI-S items and "no change" or "minimal" improvement on CaGI-C items would be meaningful. Most (n = 17/23) reported improvements in ≥ 1 CaGI-C item 1 year after treatment; for patients receiving delandistrogene moxeparvovec, most parents (n = 7/10) rated ≥ 1 item as "very much" or "much" improved compared with placebo (n = 5/13). These differences were based on descriptive reporting and were not formally tested for statistical significance. Parents identified improvements in physical abilities (i.e., running, climbing stairs, jumping) as the "most important" types of improvement.
conclusionThese findings underscore the importance of maintaining stability or achieving minimal improvements in treatment outcomes for patients with DMD. Parental experiences and perceptions provided additional insight beyond clinical outcome assessment measures, offering a complementary subjective perspective on treatment impact.
trial registrationClinicalTrials.gov identifier, NCT05096221.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.